Detail akcie Aldexa Therap online

Business Summary: Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Aldeyra Therapeutics Inc revenues was not reported. Net loss increased 1% to $24.9M. Higher net loss reflects Research and development increase of 27% to $19.3M (expense), Interest income decrease of 3% to $3.4M (income). Basic Earnings per Share excluding Extraordinary Items remained flat at -$0.42.